Progenics Pharmaceuticals Inc (NASDAQ:PGNX)

7.52
Delayed Data
As of May 25
 +0.01 / +0.13%
Today’s Change
4.60
Today|||52-Week Range
8.63
+26.39%
Year-to-Date

Five Year Financial Summary

Total Revenue

Cash & Short Term Investments

Cash From Operations

All Currency in US Dollars4 Quarter
Trend
Quarter 2
2017
Quarter 3
2017
Quarter 4
2017
Quarter 1
2018
Revenue and IncomeNet Revenues2.8M2.7M3.9M3.2M
 
 
 
 
 
Depreciation And Amortization288.0K288.0K289.0K286.0K
 
 
 
 
 
 
Operating ExpensesGross Income----------
General Expenses17.3M16.0M17.6M14.5M
 
 
 
 
 
Research And Development11.3M10.3M10.9M8.1M
 
 
 
 
 
Total Operating Expenses17.6M16.3M17.9M14.8M
 
 
 
 
 
 
Non-Operating ExpensesOperating Income-14.9M-13.6M-14.0M-11.6M
 
 
 
 
 
Extraordinary Credit0.000.00700.0K0.00
 
 
Extraordinary Charge-700.0K-700.0K---800.0K
 
 
 
 
Interest Expense On Debt1.2M1.2M1.5M1.3M
 
 
 
 
 
Other Expenses0.000.00-62.0K-63.0K
 
 
 
 
Income Taxes, Minority Interest and Extra ItemsPre-Tax Income-16.6M-15.4M-14.3M-13.4M
 
 
 
 
 
Income Taxes0.000.00-11.7M0.00
 
 
Net Income-16.6M-15.4M-2.7M-13.4M
 
 
 
 
 
 
Shares To Calculate EPSShares To Calculate EPS70.2M70.3M70.4M72.5M
 
 
 
 
 
Shares To Calculate EPS Diluted70.2M70.3M70.4M72.5M
 
 
 
 
 
 
Earnings Per ShareEPS-$0.24-$0.22-$0.04-$0.19
 
 
 
 
 
EPS Diluted-$0.24-$0.22-$0.04-$0.19